Recent News for OGEN - Oragenics, Inc.

Date Title
Jun 3 47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th
May 19 Oragenics inks deal to advance COVID-19 vaccine
May 19 Oragenics Inc. and Aragen Bioscience Enter Agreement to Accelerate Development of TerraCoV2, a SARS-CoV-2 (COVID 19) Vaccine Candidate
May 8 OGEN: Acquires Noachis Terra Inc.; Will Develop SARS-CoV-2 Vaccine…
May 4 Oragenics enters the COVID-19 vaccine game; shares up 51% premarket
May 4 Oragenics Announces New Member of the Board of Directors
May 4 Oragenics Acquires Noachis Terra Inc., To Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing "Spike Protein"
Apr 15 The Daily Biotech Pulse: Applied DNA Ships Vaccine Constructs For Animal Testing, Herceptin Biosimilar Now Available In US
Apr 15 Oragenics' AG013 flunks mid-stage study; shares down 50% premarket
Apr 15 Oragenics, Inc. Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013 for Oral Mucositis in Chemoradiation Treatment of Head and Neck Cancer
Apr 5 The Week Ahead In Biotech: Spotlight On Q1 Pre-Announcements As COVID-19 Continues To Disrupt Operations
Mar 9 OGEN: Results from Phase 2 Trial of AG013 in Early 2Q20…
Dec 31 Oragenics files for $50M equity offering
Dec 10 We're Keeping An Eye On Oragenics's (NYSEMKT:OGEN) Cash Burn Rate
Dec 3 Oragenics Inc. to Present at the LD Micro 12th Annual Main Event on December 10, 2019
Dec 2 OGEN: AG013 Phase 2 Trial Enrollment Complete…
Dec 2 Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis

Back to the Main OGEN Page...